怡达股份公告称，公司于2025年12月10日召开董事会，审议通过为控股子公司泰兴怡达2026年度办理银 行授信及开展融资租赁业务提供担保的议案，该议案尚需提交2025年第三次临时股东会审议。泰兴怡达 拟申请不超5亿元银行流动资金贷款、不超9亿元融资租赁业务融资，公司将提供连带责任保证担保，期 限均不超5年，额度可循环使用。截至公告披露日，公司及其控股子公司担保余额10.39亿元，占2024年 度经审计净资产的85.32%。 ...

（文章来源：证券日报） 证券日报网讯 12月4日晚间，怡达股份发布公告称，实际控制人的一致行动人李凤珠女士于2025年11月 13日至11月20日通过集中竞价交易减持110，000股，占总股本0.0667%，减持计划期限届满并已实施完 毕。 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 江苏怡达化学股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日披露 了《高级管理人员、实际控制人的一致行动人减持股份预披露公告》（公告编号： 2025-024），实际控制人的一致行动人李凤珠女士计划在该公告披露之日起 15 个交易日后的三个月内（即 2025 年 9 月 4 日至 2025 年 12 月 3 日）以集中竞价 方式或大宗交易方式减持公司股份合计不超过 1,050,000 股（占本公司总股本比 例 0.6370%）。 公司近日收到李凤珠女士出具的《关于减持计划期限届满暨实施情况的告知 函》，获悉上述减持计划已实施完毕。现将相关情况公告如下： 一、股东减持情况 1. 股东减持股份情况 证券代码：300721 证券简称:怡达股份 公告编号：2025-038 江苏怡达化学股份有限公司 关于实际控制人一致行动人减持计划期限届满 暨实施情况的公告 实际控制人一致行动人李凤珠女士保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 4、李凤珠女士为公司实际控制人的一致行动人，其本次减持计划的实施 ...

Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

Core Viewpoint - Yida Co., Ltd. plans to acquire 85% equity of Wanquan Biotechnology (Taizhou) Co., Ltd. from Wanquan Co., Ltd. for 24.565 million yuan, aiming to enhance its production capacity and product line in the fine chemical sector [1] Group 1 - The acquisition will make Wanquan Biotechnology a subsidiary of Yida Co., Ltd. [1] - The purpose of the acquisition is to leverage Wanquan's production experience and sales channel advantages [1] - The collaboration aims to promote the construction and investment of epoxy propylene (ethylene) derivatives in the fine chemical field [1] Group 2 - The transaction is expected to optimize Yida's capacity layout and enrich its product offerings [1] - The acquisition is intended to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan [1] Group 1: Acquisition Details - The acquisition involves the purchase of 85% equity in Wanqi Biotechnology (Taizhou) Co., Ltd. by the company's subsidiary, Taixing Yida Chemical Co., Ltd. [1] - The total investment for this acquisition is 24.565 million yuan [1] Group 2: Strategic Objectives - The acquisition is part of the company's strategy to promote high-end and refined product development [1] - The company intends to leverage Wanqi's years of production experience and sales channel advantages to advance the construction of epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - This move is expected to optimize the company's capacity layout, enrich its product line, and enhance production capabilities to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan, leveraging Wanqi's production experience and sales channels to optimize its capacity and product line [1] Group 1 - The acquisition amount is 24.565 million yuan [1] - The acquired company holds an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. [1] - The strategic goal is to promote high-end and refined product development [1] Group 2 - The collaboration will focus on the construction and investment in epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - The acquisition is expected to enhance the company's production capacity to effectively meet downstream customer demands [1] - The move is part of the company's strategy to optimize its capacity layout and enrich its product line [1]

2024年1至12月份，怡达股份的营业收入构成为：化工行业占比98.1%，其他业务占比1.9%。 截至发稿，怡达股份市值为24亿元。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 每经AI快讯，怡达股份（SZ 300721，收盘价：14.4元）11月28日晚间发布公告称，江苏怡达化学股份 有限公司控股子公司泰兴怡达化学有限公司以自有资金2456.5万元收购江苏万淇生物科技股份有限公司 持有的万淇生物科技（泰州）有限公司85%股权。本次交易完成后，标的公司成为公司控股孙公司。 （记者 曾健辉） ...

怡达股份公告，控股子公司泰兴怡达化学有限公司以自有资金2456.5万元收购江苏万淇生物科技股份有 限公司持有的万淇生物科技(泰州)有限公司85%股权。本次交易完成后，标的公司成为公司控股孙公 司。 ...

证券代码：300721 证券简称: 怡达股份 公告编号：2025-037 江苏怡达化学股份有限公司 关于控股子公司收购股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 1、 江苏怡达化学股份有限公司（以下简称"怡达股份"、"公司"）控股 子公司泰兴怡达化学有限公司（以下简称"泰兴怡达"）以自有资金 2,456.50 万元收购江苏万淇生物科技股份有限公司（以下简称"万淇股份"）持有的万淇 生物科技（泰州）有限公司（以下简称"标的公司"）85%股权。本次交易完成 后，标的公司成为公司控股孙公司。本次收购事项不构成关联交易，亦不构成《上 市公司重大资产重组管理办法》规定的重大资产重组事项。 2、 公司于 2025 年 11 月 28 日召开了第五届董事会第七次会议，审议通过 了《关于控股子公司收购股权的议案》。根据《深圳证券交易所创业板股票上市 规则》以及《公司章程》等有关规定，本次收购事项无需提交股东会审议。 | 公司名称 | 江苏万淇生物科技股份有限公司 | | --- | --- | | 企业类型 | 股份有限公司（非上市） | | 注 ...